Omeros Swings to Profit on Novo Nordisk Deal and YARTEMLEA Launch
Event summary
- Omeros reported a net income of $86.5 million for Q4 2025, reversing a $31.4 million loss in the same period of 2024.
- The company received a $240 million upfront payment from Novo Nordisk for the zaltenibart transaction.
- YARTEMLEA (narsoplimab-wuug) was approved by the FDA on December 23, 2025, for treating TA-TMA in adults and children aged two years and older.
- Omeros reduced its debt by $77.1 million, or 46.7%, from December 31, 2024, to December 31, 2025.
The big picture
Omeros' strategic shift from R&D-focused to commercial-stage is underscored by the YARTEMLEA launch and Novo Nordisk partnership. The $240 million upfront payment and potential milestone payments highlight the value of its MASP-3 program, while debt reduction strengthens financial flexibility. The biotech sector's focus on orphan drug approvals and partnerships for large-market indications aligns with Omeros' current trajectory.
What we're watching
- Regulatory Approval
- Whether the EMA will approve YARTEMLEA for TA-TMA in mid-2026, expanding its market reach into Europe.
- Commercial Execution
- The pace at which Omeros can scale commercial distribution and sales of YARTEMLEA across the U.S.
- Pipeline Development
- How Omeros progresses its OncotoX-AML program, targeting acute myeloid leukemia with a novel therapeutic candidate.
Related topics